---
run_id: halo-evidence-vs-diagnosis-validation-v9-vanilla-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: vanilla
run_number: 5
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 501
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `vanilla`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 501, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

### The Recommendation
You should commit to the Claim File Review. While your revenue and usage metrics are trending upward, they are currently "noisy" indicators. The expansion bookings are skewed by temporary pricing incentives (artificial demand), and the usage spikes are driven by managers performing audits rather than adjusters executing workflows (phantom utility).

The Claim File Review is the only proposed action that penetrates the "entangled" evidence to find the ground truth: **Does DraftPath actually solve a problem for the end-user, or is it merely a sales tool that looks good in a demo?** By analyzing whether suggestions are accepted, overridden, or "impossible to explain," you will determine if the product has a fundamental utility gap (especially in health-liability) or if it is simply an enablement problem. This provides the only reliable foundation for next year's budget; scaling a product that adjusters abandon after two days is a recipe for massive churn once the "bundle price" honeymoon ends.

### The Strongest Reason Against It
The Claim File Review is a slow, manual, and qualitative process. Unlike the Usage Quality Sprint or the Commercial Cleanroom, it does not provide a clean "Go/No-Go" metric for the board in twelve days. It risks producing nuanced, anecdotal feedback that is harder to translate into a budget line item than a percentage increase in retention or a dollar amount of "clean" expansion.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" feedback in the health-liability segment is an isolated edge case and that the primary driver of the current growth is purely a pricing fluke. If your account managers report that customers are renewing *solely* because of the discount and not because they perceive value in DraftPath, the problem is no longer a "product-market fit" question—it is a pricing and packaging failure. In that scenario, you must validate the commercial viability of the feature before spending another developer hour on it.
